virtual seminars it couldn't be easier

Presented by: Christophe Echeverri, PhD CEO and CSO Cenix Bioscience GmbH Dresden, Germany

Moderated by: David Dorris, PhD Director of RNAi Technologies Ambion, Inc. Austin, Texas

Registration for the live event is now closed. However, if you are interested in viewing an online recording which contains the entire presentation, including audio, you may purchase this for $169 USD. Please click the button below and you will be emailed information on how to access the recorded event. MAC USERS: Unfortunately at this time the recordings cannot be viewed on the MAC OS.

Thisonline real-time presentation focused on combining genome-wide HT-RNAi with high-content readout assays in human cells and model organisms to accelerate target discovery and target validation.

As a research tool and potential therapeutic, RNA interference (RNAi) offers an unprecedented combination of high potency, specificity, scalability, wide cross-species applicability, and excellent experimental reproducibility. RNAi is thus rapidly becoming the method of choice for a wide range of biomedical applications, replacing conventional antisense and ribozyme technologies and emerging as a powerful tool for functional genomics research. RNAi-based screens to identify novel disease-relevant genes can now be carried out in several model organisms, including C. elegans and Drosophila cells. Libraries of siRNA molecules and shRNA-encoding constructs are being constructed that permit screening directly in human cells. Since these screens can either be focused on specific gene families or run in a comprehensive genome-wide manner, they offer a level of control and efficiency previously unattainable. Further, by offering a direct, causal link between gene and phenotype, target genes identified by RNAi inherently carry clearer physiological and therapeutic relevance, i.e., superior levels of validation. To garner the greatest benefit from RNAi as a functional genomics tool, appropriate strategies for RNAi assays, as well as optimized RNAi reagents, are necessary.

The 1½–hour presentation addressed:

An extensive Q&A session, with worldwide participation followed.

Participate in this Virtual Seminar. You can attend this real-time tutorial from anywhere you have an Internet connection.

One Low Registration Fee of $149 entitled you to a site registration, which enables you and unlimited additional colleagues and staff to participate, whether gathered around a computer or in a conference room with speakerphone and screen.

It Couldn’t Be Easier! You’ll view the presentation over your Web browser. On a separate telephone line (which can be put on speakerphone), you will hear the audio and be able to ask questions of the presenter and moderator. You can also submit questions by your keyboard.

Time Well Spent! No travel, no time away. GEN’s hour-and-a-half virtual seminars are authoritative presentations by industry leaders that include ample time for questions and discussion. Registrations will be limited to ensure interactive participation.

Presented by Genetic Engineering News & ASSAY and Drug Development Technologies Journal